Defining NASH from a multi-omics systems biology perspective

Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Niu, Lili;
Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Sulek, Karolina;
Affiliation
2 Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany; vasilopoulou@biochem.mpg.de (C.G.V.); Florian.Meier@med.uni-jena.de (F.M.)
Vasilopoulou, Catherine G.;
Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Santos, Alberto;
ORCID
0000-0003-4230-5753
Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Wewer Albrechtsen, Nicolai J.;
ORCID
0000-0001-6323-9041
Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Rasmussen, Simon;
Affiliation
2 Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany; vasilopoulou@biochem.mpg.de (C.G.V.); Florian.Meier@med.uni-jena.de (F.M.)
Meier, Florian;
Affiliation
1 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; karolina.sulek@regionh.dk (K.S.); alberto.santos@sund.ku.dk (A.S.); nicolai.albrechtsen@sund.ku.dk (N.J.W.A.); simon.rasmussen@cpr.ku.dk (S.R.); mmann@biochem.mpg.de (M.M.)
Mann, Matthias

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2021 by the authors.

Use and reproduction:
This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.